Carcinoma with shared pathologic characteristics of both hepatocellular carcinoma and cholangiocarcinoma  by Hiraoka, Atsushi et al.
VIILUME 66, NUMBER 6, NIIVEMBER/DEc'EMBER 2005 
Case Report 
Carcinoma with Shared Pathologic Characteristics 
of Both Hepatocellular Carcinoma and 
Cholangiocarcinoma 
Atsushi Hiraoka, MD1; Kiyotaka Kurose, MD1; Teru Kumagi, MD~; 
Masashi Hirooka, MD~; Tomoyuki Yokota, MD~; Toshiteru Fujiwara, MD~; 
Sachiko Utsunomiya, MD1; Mami Hirata, MD2; Hiromi Ohtani, MD3; 
Kojiro Michitaka, MD1; Norio Horiike, MD1; Nobuaki Kobayashi, MD3; 
and Morikazu Onji, MD 1 
7Third Department of Internal Medicine, Ehime University School f Medicine, Ehime, 
Japan; 2Department of Internal Medicine, Matsuyama Johto Hospital, Ehime, Japan; 
and 3First Department of Surgery, Ehime University School f Medicine, Ehime, Japan 
ABSTRACT 
Background: ¢z-Fetoprotein (AFP) is a useful marker of hepatocellular car- 
cinoma (HCC), and protein induced by vitamin K absence or antagonist II 
(PIVKA-II) and fucosylated AFP (AFP-L3) are specific tumor markers. 
Objective: The aim of this article was to report a case of intrahepatic 
cholangiocarcinoma (CC) with high levels of expression of AFP, AFP-L3, and 
PIVKA-II. 
Methods: A 70-year-old man weighing 66 kg with a diagnosis of intrahepatic 
CC presented with a liver tumor 4.0 cm in diameter and elevated concentrations 
of carbohydrate antigen 19-9 (575 U/mL), PIVKA-II (379 mAU/mL), and AFP 
(497 ng/mL; AFP-L3, 88.1%). On extended medial hepatic segmentectomy, micros- 
copy showed that the tumor was a CC without HCC. The patient subsequently un- 
derwent immunohistochemical assessments u ing cytokeratin-19, epithelial mem- 
brane antigen (EMA), hepatocyte paraffin-1 (HP-1), PIVKA-II, and AFP. 
Results: In all specimens, desmoplasia was observed. However, results of 
immunohistochemistry showed positive results for cytokeratin-19 and EMA; 
HP-1 results were negative. Results of PIVKA-II and AFP testing in the tumor were 
positive. 
Conclusions: The case presented here showed characteristics of CC and 
HCC, whereas the histologic expression of the tumor suggested CC. Based on 
the literature search, this is the first known report of a case of a CC expressing 
AFP and PIVKA-II confirmed on immunohistochemical staining. This case is 
interesting with regard to the ability of the progenitor cells to differentiate HCC 
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INTRODUCTION 
cz-Fetoprotein (AFP) is a fetal serum protein produced mainly in the fetal iver and 
yolk sac, and is a useful marker for hepatocellular carcinoma (HCC). Fucosylat- 
ed AFP (L3-1ectin binding AFP [AFP-L3]) 1,2 and protein induced by vitamin K ab- 
sence or antagonist ii (PIVKA-II) are specific markers for HCC. 3A Aoyagi et al 2 
found that specificity of AFP-L3 for HCC was 86%, and Kuromatsu et al 5 found that 
it was 92.8% for PIVKA-II. 
A combined HCC-cholangiocarcinoma (CC) has histologic and clinical char- 
acteristics. 6-9 However, based on a literature search of MEDLINE (key terms: 
PIVKA-II, des-gamma-carboxy prothrombin, and cholangiocarcinoma; years: 1993- 
2005), there have been no reports of a CC without a component of HCC produc- 
ing AFP and PIVKA-II. 
The aim of this article was to describe a patient with a primary intrahepatic 
CC and high levels of AFP-L3 and PIVKA-II, in whom we found AFP and PIVKA-II 
localized in tumor cells on immunohistochemical st ining of resected tumor. 
CASE PRESENTATION 
A 70-year-old Japanese man weighing 66 kg presented to his primary care prac- 
titioner with epigastralgia and loss of appetite on August 5, 2003. Although he 
had no history of alcohol dependency, liver function test results from his pri- 
mary care physician showed elevated serum alanine and aspartate aminotrans- 
ferases, alkaline phosphatase, total bilirubin, and ~-glutamyl transpeptidase con- 
centrations. Sonography and computed tomography (CT) showed stones in the 
common bile duct and an intrahepatic tumor (4th segment). After 4 days of non- 
invasive treatment with an antibiotic, the patient's total bilirubin concentration 
was decreased to near normal, and the epigastralgia had resolved. However, the 
patient was admitted to Ehime University Hospital, Ehime, Japan, on August 9 
for additional investigation of the intrahepatic tumor and endoscopic removal 
of the common bile duct stones. 
Physical examination revealed no abnormalities. However, his concentra- 
tions of serum AFP (497 ng/mL [normal value (NV), <20 ng/mL]), ratio of AFP-L3 
(88.1% [NV, <15%]), plasma PIVKA-II (379 mAU/mL [NV, <40 mAU/mL]), serum 
carcinoembryonic antigen (17 ng/mL [NV, <5 ng/mL]), and serum carbohydrate 
antigen 19-9 (CA 19-9) (575 U/mL [NV, <37 U/mL]) were all increased. Hepatitis 
viral markers were not detected (Table). A common bile duct stone was found 
on endoscopic retrograde cholangiopancreatography on August 21 and was 
removed endoscopically. At that time, contrast-enhanced sonography showed 
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Table. Laboratory data on admission. 
Parameter Value Parameter Value 
WBCs 7100 cells/tJL ALP 893 IU/L 
Neutrophils 70.2% 7-GTP 754 IU/L 
Basophils 0.7% LAP 87 IU/L 
Eosinophils 1.7% ChE 106 IU/L 
Lymphocytes 18.7% ZTT 6 U 
Monocytes 8.7% TTT 1 U 
RBCs 400 x 104 cells/tJL TC 201 mg/dL 
Hemoglobin 13.3 g/dL TG 106 mg/dL 
Hematocrit 38.7% IgG 1550 mg/dL 
Platelets 19.6 x 104 cells/tJL IgA 87 mg/dL 
PT 81.3% IgM 357 mg/dL 
Bleeding time 1.5 min Na 135 mEq/L 
ESR 18/43 mm K 4.3 mEq/L 
AFP 497 ng/mL CI 105 mEq/L 
AFP-L3 88.1% BUN 16 mg/dL 
PIVKA-II 379 mAU/mL Creatinine 1.1 mg/dL 
CEA 17 ng/mL Fe 98 tJg/dL 
CA 19-9 575 U/mL Ferritin 48 ng/dL 
TP 7.1 g/dL CRP 6.3 mg/dL 
Albumin 3.1 g/dL HbAlc 4.5% 
Total bilirubin 1.3 mg/dL FPG 96 mg/dL 
D-Bil 0.8 mg/dL HCV Ab Negative 
AST 67 IU/L HBsAg Negative 
ALT 108 IU/L HBcAb Negative 
LDH 163 IU/L 
WBCs = white blood cells; RBCs = red blood cells; PT = prothrombin time; ESR = erythrocyte sedimen- 
tation rate; AFP = c~-fetoprotein; AFP-L3 = c~-fetoprotein L3; PIVKA-II = protein induced by vitamin K 
absence or antagonism II; CEA = carcinoembryonic antigen; CA 19-9 = carbohydrate antigen 19-9; 
TP = total protein; D-Bil = direct bilirubin; AST = aspartate aminotransferase; ALT = alanine amino- 
transferase; LDH = lactate dehydrogenase; ALP = alkaline phosphatase; 7-GTP = 7-guanosine triphos- 
phate; LAP = leukocyte alkaline phosphatase; ChE = cholinesterase; ZTT = zinc sulfate turbidity test; 
TTT = thymol turbidity test; TC = total cholesterol; TG = triglycerides; Ig = immunoglobulin; BUN = blood 
urea nitrogen; CRP = C-reactive protein; HbA 1 c = glycosylated hemoglobin; FPG = fasting plasma glucose; 
HCV Ab = hepatitis C virus antibody; H BsAg = hepatitis B surface antigen; H BcAb = hepatitis B core antibody. 
the tumor enhanced gradually from the outside, which has been described as a 
defect in the late phase. Dynamic CT, superparamagnetic iron oxide magnetic 
resonance imaging, CT angiography (CTA), and CTA portography (CTAP) were 
performed. Tumor staining was observed on angiography, and CTA showed a 
gradual enhancement from the outside of the tumor, which was determined to 
be the result of a defect in CTAP (Figure 1). 
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Figure 1. (A) Computed tomographic angiography (CTA) showing the tumor en- 
hanced gradually from the outside and nontypical findings for a hepato- 
cellular carcinoma. (B) CTA portography showing a defect consistent with 
the tumor. 
Extended medial segmentectomy of the liver and cholecystectomy performed 
on September 16 showed direct invasion of the colon transversum and coinci- 
dental resection of the mass. Metastasis of the lymph nodes was not detected, 
and no other intrahepatic tumors were found during the surgery or on intra- 
operative sonography. Macroscopy of the resected specimen revealed that the 
tumor measured 4.6 x 4.3 cm, with no capsular formation. All specimens of 
resected hepatic tumor obtained uring the surgery were immediately fixed in 
10% formalin, cut on the largest surface, grossly observed, embedded in paraf- 
fin, and stained with hematoxylin-eosin a d periodic acid-Schiff. Microphotog- 
raphy revealed marked desmoplasia (Figure 2). In addition, the expression and 
localization of cytokeratin-19, as well as epithelial membrane antigen (EMA) 
(specific antibodies for cholangiocytes 1°,11) and hepatocyte paraffin-1 (HP-1) 
(a specific antibody for hepatocytes12), were found on immunohistochemistry. 
Furthermore, xpression of AFP and PIVKA-II was found on immunohistochem- 
istry using an antibody-labeled streptavidin-biotin method. 13,14 
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Figure 2. Microphotography of the resected specimen revealed the tumor to be an 
adenocarcinoma with marked fibrous stroma. (Hematoxylin and eosin; magni- 
fication x40 [A] and x 100 [B].) 
The presence of serum hepatitis B surface antigen (HBsAg), hepatitis B core 
antibody, and hepatitis C virus (HCV) antibody was assessed using enzyme-linked 
immunoassay kits (AxSYM HBsAg, Dainabot, Tokyo, Japan; Architect anti-HBc, 
Abbott Japan, Matsudo, Japan; and Imcheck-F-HCV, Kokusai-shinyaku, Kobe, Japan, 
respectively). 
All specimens were fixed in formalin. Hepatic immunostaining for PIVKA-II 
(Eisai Company Ltd., Tokyo Japan), AFP (Nichirei, Tokyo, Japan), EMA (Dako 
Japan Company, Ltd., Kyoto, Japan), HP-1 (Dako Japan Company, Ltd.), and 
cytokeratin-19 (Immunotech, Marseille, France) was performed using an antibody- 
labeled streptavidin-biotin method. 
RESULTS 
Results of cytokeratin-19 and EMA testing were positive in all of the specimens 
of the tumor (Figures 3A and 4A), whereas results of HP-1 testing were negative 
(Figure 4B). The appearance was different from that of the scirrhous pattern of 
an HCC. As a result, we diagnosed the tumor as a moderate differentiated type 
of CC, with invasion to the colon submucosa, portal vein lymphoduct, and vein. 
The tumor was not a scirrhous type of HCC and thought to be differentiated 
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Figure 3. 
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(A) Cytokeratin-19 testing was positive in all specimens, with positive cells 
stained (diaminobenzidine [DAB]; magnification x 40). (B) Immunostaining 
for a-fetoprotein, shown diffusely stained (DAB; magnification x40). 
(C) Immunostaining for protein induced by vitamin K absence or antago- 
nism II, which was faintly expressed and stained (DAB; magnification x40). 
All staining was performed on mirror specimens. 
from cholangiocytes. Furthermore, the tumor specimens expressed AFP and 
PIVKA-II (Figures 3B and 3C). 
DISCUSSION 
As mentioned previously, AFP is a marker of HCC, and AFP-L31,2 and PIVKA-II 3-5 
are specific tumor markers for HCC. PIVKA-II expression is increased in vitamin 
K-deficient patients, those receiving avitamin K antagonist, and those with HCC. 15 
In the patient presented here, jaundice was not apparent at admission to Ehime 
University Hospital, although high levels of PIVKA-II continued and we did not 
detect the markers of a typical HCC in any of the resected tumor specimens. 
Based on the literature search, there have been no reports of a CC producing 
AFP and PIVKA-II. We found elevated levels of PIVKA-II, AFP-L3, carcinoembryonic 
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Figure 4. (A) Epithelial membrane antigen was positive in all specimens of the tumor, 
with positive cells stained (diaminobenzidine [DAB]; magnification x40). 
(B) Hepatocyte paraffin-1 (HP-1) testing was negative in all specimens of 
the tumor. The nonneoplastic part was positive for HP-1 (stained) (DAB; 
magnification x 40). 
antigen, and CA 19-9, whereas  f indings on dynamic  CT and cont ras t -enhanced 
sonography  showed non ident ica l  enhancements  in the  ear ly  vascu lar  phase  
and a defect  in the  por ta l  phase  such  as a typ ica l  HCC. Therefore ,  we init ia l ly 
suspected  a combined  HCC-CC, wh ich  has  h is to log ic  features  of both  HCC and 
CC. 7-9 Koj iro 16 c lass i f ied combined  HCC-CC into 3 types  macroscop ica l ly  and 
h isto log ica l ly :  (1) HCC and CC are c lear ly  d i s t ingu ished;  (2) HCC and CC are 
cont iguous  and share  t rans i t iona l  features;  and (3) cancer  cel ls can be assessed  
as e i ther  HCC or CC and are cons idered  to be an in termed iate  type.  The histo-  
logic appearance  of the tumor  in the case  presented  here  dif fered from a typ ica l  
combined  HCC-CC in that  the  morpho log ic  features  were  typ ica l  of a moder -  
ate ly  d i f fe rent ia ted  CC. On immunoh is tochemica l  s ta in ing for AFP and PIVKA-II, 
we observed  doub le -s ta in ing  wi th  cytokerat in -19 and EMA in ser ia l  s l ices.  On 
immunochemica l  assessment ,  cy okerat in -19 and EMA, wh ich  are expressed  in 
CC cells,  were  detected .  Thus,  desp i te  the  typ ica l  CC features  on histo logy,  the  
assoc ia t ion  of both  HCC and CC character i s t i cs  might  present  a new concept  
for recogn iz ing  combined  HCC-CC. 
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Regarding the etiology of combined HCC-CC, Goodman et al 7 noted that neo- 
plastic progenitor cells with the ability to differentiate bidirectionally to HCC 
and CC might develop into both malignant cell types. Theise et a117 reported 
hepatic s tem cell malignancies in 4 adults. As for other malignant umors  pro- 
ducing AFP and PIVKA-II, a few cases of gastric cancer without typical HCC and 
combined HCC-CC have been reported.  18,19 The ability of those malignancies to 
produce serum protein was considered to be due to the strong similarity to 
hepatic cells. 2° Ishikura et a121'22 speculated the reason to be that the liver is 
derived from the foregut part of the stomach,  and that hepatocytes  and cholan- 
giocytes are thought to be derived from the same stem cells. Thus, regarding 
differentiation of hepatocytes  and bile duct cells, a new classification of com- 
bined HCC-CC should be added to that proposed by Kojiro 16 pending the iden- 
tification of other cases. 
CONCLUSIONS 
The case presented here showed characterist ics of CC and HCC, whereas the his- 
tologic expression of the tumor suggested CC. Based on the l iterature search, 
this is the first known report  of a case of a CC expressing AFP and PIVKA-II con- 
f irmed on immunohistochemical  staining. This case is interesting with regard to 
the ability of the progenitor cells to differentiate HCC and CC. 
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